The Highly Productive

Thermothelomyces heterothallica C1 filamentous fungi influenza vaccine recombinant protein expression targeted influenza hemagglutinin trimeric influenza hemagglutinin

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
20 Jan 2022
Historique:
received: 29 10 2021
revised: 11 01 2022
accepted: 12 01 2022
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 27 2 2022
Statut: epublish

Résumé

(1) Influenza viruses constantly change and evade prior immune responses, forcing seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine manufacturing technologies are too slow and/or expensive to quickly adapt to mid-season changes in the virus or to the emergence of pandemic strains. Therefore, cost-effective vaccine technologies that can quickly adapt to newly emerged strains are desirable. (2) The filamentous fungal host

Identifiants

pubmed: 35214607
pii: vaccines10020148
doi: 10.3390/vaccines10020148
pmc: PMC8877961
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nature. 1987 May 7-13;327(6117):59-61
pubmed: 3472080
Vaccine. 2005 Dec 30;23(50):5708-24
pubmed: 16154667
Int J Parasitol. 2017 Jun;47(7):435-446
pubmed: 28153778
Mycologia. 2015 May-Jun;107(3):619-32
pubmed: 25661719
Hum Vaccin Immunother. 2018;14(8):1874-1882
pubmed: 29672213
Trends Ecol Evol. 2017 Jan;32(1):55-67
pubmed: 28029378
PLoS Pathog. 2010 Jan 29;6(1):e1000745
pubmed: 20126449
Science. 2004 Mar 19;303(5665):1838-42
pubmed: 14764886
Mol Cell Proteomics. 2019 Dec;18(12):2348-2358
pubmed: 31604803
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10224-8
pubmed: 9707628
Rev Sci Tech. 2000 Apr;19(1):310-7
pubmed: 11189723
J Immunol. 1986 Jan;136(1):58-65
pubmed: 3079611
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862331
Rev Sci Tech. 2014 Aug;33(2):569-81
pubmed: 25707184
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Front Public Health. 2020 Jul 29;8:383
pubmed: 32850602
Ther Adv Vaccines. 2015 Jul;3(4):97-108
pubmed: 26478817
Appl Environ Microbiol. 2013 Feb;79(4):1316-24
pubmed: 23241981
Arch Med Res. 2017 Nov;48(8):701-716
pubmed: 29398104
Pathogens. 2016 Dec 06;5(4):
pubmed: 27929449
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
EBioMedicine. 2021 Dec;74:103699
pubmed: 34801965
Hum Vaccin Immunother. 2018;14(8):1840-1847
pubmed: 29641358
Vaccines (Basel). 2021 Jun 15;9(6):
pubmed: 34203630
Vaccine. 2008 Sep 12;26 Suppl 4:D49-53
pubmed: 19230160
Blood. 2002 Aug 15;100(4):1153-9
pubmed: 12149191
J Immunol. 2016 Nov 1;197(9):3575-3585
pubmed: 27671110
Nat Biotechnol. 2011 Oct 02;29(10):922-7
pubmed: 21964414
J Virol. 1986 Dec;60(3):833-9
pubmed: 3783818
N S W Public Health Bull. 2011 Jul;22(5-6):113-7
pubmed: 21781618
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Virology. 1990 Mar;175(1):59-68
pubmed: 2309452
Vaccines (Basel). 2021 Sep 29;9(10):
pubmed: 34696209
J Virol. 2014 Mar;88(5):2844-57
pubmed: 24371052
Vaccines (Basel). 2021 Mar 13;9(3):
pubmed: 33805749
Biotechnol Bioeng. 2007 Aug 1;97(5):1028-38
pubmed: 17221887
Anal Bioanal Chem. 2021 Dec;413(30):7559-7585
pubmed: 34739558
Microbiol Rev. 1992 Mar;56(1):152-79
pubmed: 1579108
Hum Vaccin Immunother. 2017 Jul 3;13(7):1640-1652
pubmed: 28532276
Mol Ther. 2006 Apr;13(4):776-85
pubmed: 16414309
Annu Rev Biochem. 2000;69:531-69
pubmed: 10966468
Bull World Health Organ. 1974;51(1):1-11
pubmed: 4218138
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Front Immunol. 2019 Mar 27;10:594
pubmed: 30972078
Front Immunol. 2015 Jul 20;6:367
pubmed: 26257735
Front Immunol. 2021 Aug 31;12:710647
pubmed: 34531860
Crit Rev Biotechnol. 2016;36(1):59-69
pubmed: 25025273
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Metab Eng. 2020 Sep;61:416-426
pubmed: 31078793

Auteurs

Gabor Keresztes (G)

Dyadic International Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477, USA.

Mark Baer (M)

EnGen Bio LLC, 61 Avondale Ave., Redwood City, CA 94062, USA.

Mark R Alfenito (MR)

EnGen Bio LLC, 61 Avondale Ave., Redwood City, CA 94062, USA.

Theo C Verwoerd (TC)

Dyadic International Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477, USA.

Andriy Kovalchuk (A)

VTT Technical Research Centre of Finland Ltd., P.O. Box 1000, 02044 Espoo, Finland.

Marilyn G Wiebe (MG)

VTT Technical Research Centre of Finland Ltd., P.O. Box 1000, 02044 Espoo, Finland.

Tor Kristian Andersen (TK)

Institute of Clinical Medicine, University of Oslo, 0027 Oslo, Norway.

Markku Saloheimo (M)

VTT Technical Research Centre of Finland Ltd., P.O. Box 1000, 02044 Espoo, Finland.

Ronen Tchelet (R)

Dyadic International Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477, USA.

Richard Kensinger (R)

Sanofi Pasteur, 1541 Ave. Marcel Mérieux, 69280 Marcy l'Etoile, France.

Gunnveig Grødeland (G)

Institute of Clinical Medicine, University of Oslo, 0027 Oslo, Norway.
Department of Immunology and Transfusion Medicine, Oslo University Hospital, 0027 Oslo, Norway.

Mark Emalfarb (M)

Dyadic International Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477, USA.

Classifications MeSH